Dimebon is an orally-available drug, approved in Russia for use as a non-selective antihistamine, that has shown promise in the treatment of neurodegenerative diseases, including Alzheimers and Huntingtons disease. In addition to preventing the onset and progression of disease by being neuroprotective, dimebon appears to promote clinical improvement by increasing cognitive function. At the cellular level, dimebon appears to have diverse effects, inhibiting the neurotoxic action of beta-amyloid and blocking L-type calcium channels, inhibiting NMDA-type glutamate receptors, and preventing mitochondrial leakage.
Die Preise verstehen sich exkl. Versandkosten, eventuell anfallender Kühlmittelpauschale sowie der jeweils geltenden Mehrwertsteuer